An Open-Label Study to Evaluate the Safety and Efficacy of PRX-08066 in Patients With Pulmonary Hypertension and Chronic Obstructive Pulmonary Disease

Epix Pharmaceuticals

Status and phase

Terminated

Phase 2

Conditions

COPD

Pulmonary Hypertension

Treatments

Drug: PRX-08066

Study type

Interventional

Funder types

Industry

Identifiers

NCT00677872

PRX-08066-202

Details and patient eligibility

About

A 3-month open label study to evaluate the safety and efficacy of PRX-08066 in patients with pulmonary hypertension and COPD.

Enrollment

40 estimated patients

Sex

All

Ages

40+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Men and Women >40 years of age
Diagnosis of COPD with an FEV1 above 20% and less than 65% of predicted normal and an FEV1-to-FVC ratio of less than 70%
Diagnosis of pulmonary hypertension based on echocardiography within the last 6 months or by cardiac catheterization within the last 12 months
New York Heart Association(NYHA)Class II or III
Screening LVEF>55%, obtained by any appropriate method within 6 months of screening
Baseline 6MWT distance>150m and <450m
Written informed consent from each subject prior to the initiation of any study-related procedure
Documented negative results (within 12 months)and Hepatitis B and Hepatitis C Serology

Exclusion criteria

Treatment for pulmonary hypertension with epoprostenol (prostacyclin), trepostinil (Remodulin), iloprost (Ventavis), bosentan (Tracleer), ambrisentan (Letairis), sildenafil (Viagra), tadalafil (Cialis), or vardenafil (Levitra) within the 30 days prior to study entry
Presence or history of any of the following cardiovascular co-morbidities or conditions: Un-controlled systemic hypertension at screening; unstable cardiovascular disease including intermittent atrial fibrillation or unstable angina within the 4 weeks prior to screening; amyloidosis, hypertrophic obstructive cardiomyopathy, restrictive cardiomyopathy, or constrictive pericarditis; history of myocardial infarction, coronary artery bypass graft surgery, or percutaneous cardiac intervention within the 3 months prior to screening; significant valvular heart disease; cerebrovascular accident or transient ischemic attack within 3 months prior to screening
COPD exacerbation less than 1 month prior to screening
Exercise tolerance limited by non-cardiac causes
Clinically significant psychiatric, addictive, neurologic disease or condition
Chronic renal impairment or renal insufficiency
No clinically significant laboratory abnormalities
Subjects currently being treated for PH with prostnoids, PDE-5 inhibitors and or endothelin receptor antagonist. The use of PDE-5 inhibitors "as needed" for erectile dysfunction is acceptable as long as the subject does not take the medication within 72 hours of an efficacy assessment. Other concomitant medications are allowed provided the subject has been on a stable dose regimen for at least 4 weeks prior to enrollment and the regimen continues and remains stable during the treatment and follow-up periods.
History of nasal airway mass, septal perforation, chronic sinusitis, lidocaine allergy or current nasal passage condition that would decrease the safety or tolerability of a naso-esophageal catheter
The subject has the presence, or history, of malignancy that required significant medical intervention within the preceding 3 months and/or is likely to result in death within the next 2 years
The receipt of any investigational medication within 30 days prior to screening or anytime during the course of the study
Women cannot be pregnant or breastfeeding